Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sangamo Therapeutics, Inc. SGMO -- Ignore unavailable to you. Want to Upgrade?

To: tom pope who wrote (217)	6/26/2007 12:34:42 PM
From: bob zagorin	Respond to of 368

i think that was cannacord adams (sp) can't find the original right now.. but here's more.. _______________ Sangamo Biosciences "buy" Tuesday, June 26, 2007 9:23:16 AM ET Cantor Fitzgerald NEW YORK, June 26 (newratings.com) - In a research note published yesterday, analyst Pamela Bassett of Cantor Fitzgerald reiterates her "buy" rating on Sangamo Biosciences Inc (SGMO.NAS). The target price is set to $17. _______________________________ Sangamo BioSciences "strong buy" Tuesday, June 26, 2007 8:36:28 AM ET JMP Securities NEW YORK, June 26 (newratings.com) - In a research note published yesterday, analysts at JMP Securities reiterate their "strong buy" rating on Sangamo BioSciences Inc (SGMO.NAS). The target price is set to $15.